Multivariate model evaluating outcomes in single mismatch transplants including and excluding C*03:03/C*03:04
| . | 7/8 C*03:04/C*03:04 mismatch . | 7/8 HLA-A, -B, or -DRB1 mismatch . | 7/8 C-antigen mismatch . | 7/8 Other C-allele mismatch . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| n = 134 . | n = 959 . | n = 700 . | n = 61 . | |||||||
| HR . | HR . | 95% CI . | P . | HR . | 95% CI . | P . | HR . | 95% CI . | P . | |
| OS* | 1.00 | 1.33 | (1.05-1.68) | .02 | 1.40 | (1.10-1.79) | <.01 | 1.46 | (1.00-2.11) | .05 |
| DFS† | 1.00 | 1.27 | (1.00-1.60) | .05 | 1.32 | (1.05-1.67) | .02 | 1.34 | (0.93-1.93) | .12 |
| TRM‡ | 1.00 | 1.47 | (1.09-1.97) | .01 | 1.47 | (1.08-1.98) | .01 | 1.52 | (0.95-2.43) | .08 |
| 3-4 aGVHD§ | 1.00 | 1.84 | (1.27-2.67) | .001 | 1.55 | (1.06-2.36) | .02 | 1.79 | (1.02-3.15) | .05 |
| 2-4 aGVHD| | | 1.00 | 1.33 | (1.02-1.73) | .03 | 1.18 | (0.90-1.54) | .23 | 1.60 | (1.06-2.43) | .03 |
| Absence of neutrophil engraftment at day 28¶ | 1.00 | 1.89 | (0.88-4.17) | .11 | 2.04 | (0.93-4.55) | .07 | 1.89 | (0.61-5.88) | .27 |
| Relapse# | 1.00 | 1.09 | (0.69-1.45) | .98 | 1.09 | (0.76-1.59) | .63 | 1.07 | (0.59-1.94) | .82 |
| cGvHD** | 1.00 | 1.13 | (0.87-1.48) | .37 | 1.11 | (0.84-1.46) | .47 | 1.18 | (0.76-1.83) | .47 |
| . | 7/8 C*03:04/C*03:04 mismatch . | 7/8 HLA-A, -B, or -DRB1 mismatch . | 7/8 C-antigen mismatch . | 7/8 Other C-allele mismatch . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| n = 134 . | n = 959 . | n = 700 . | n = 61 . | |||||||
| HR . | HR . | 95% CI . | P . | HR . | 95% CI . | P . | HR . | 95% CI . | P . | |
| OS* | 1.00 | 1.33 | (1.05-1.68) | .02 | 1.40 | (1.10-1.79) | <.01 | 1.46 | (1.00-2.11) | .05 |
| DFS† | 1.00 | 1.27 | (1.00-1.60) | .05 | 1.32 | (1.05-1.67) | .02 | 1.34 | (0.93-1.93) | .12 |
| TRM‡ | 1.00 | 1.47 | (1.09-1.97) | .01 | 1.47 | (1.08-1.98) | .01 | 1.52 | (0.95-2.43) | .08 |
| 3-4 aGVHD§ | 1.00 | 1.84 | (1.27-2.67) | .001 | 1.55 | (1.06-2.36) | .02 | 1.79 | (1.02-3.15) | .05 |
| 2-4 aGVHD| | | 1.00 | 1.33 | (1.02-1.73) | .03 | 1.18 | (0.90-1.54) | .23 | 1.60 | (1.06-2.43) | .03 |
| Absence of neutrophil engraftment at day 28¶ | 1.00 | 1.89 | (0.88-4.17) | .11 | 2.04 | (0.93-4.55) | .07 | 1.89 | (0.61-5.88) | .27 |
| Relapse# | 1.00 | 1.09 | (0.69-1.45) | .98 | 1.09 | (0.76-1.59) | .63 | 1.07 | (0.59-1.94) | .82 |
| cGvHD** | 1.00 | 1.13 | (0.87-1.48) | .37 | 1.11 | (0.84-1.46) | .47 | 1.18 | (0.76-1.83) | .47 |
In bold are shown statistically significant comparisons made with the 7/8 C*03:04/C*03:04 mismatch group.
Adjusted for graft type, Karnofsky score, time from diagnosis to transplantation, and year of transplantation.
Adjusted for disease stage, graft type, Karnofsky score, and year of transplantation.
Adjusted for graft type, Karnofsky score, and year of transplantation.
Adjusted for GVHD prophylaxis, in vivo T-cell depletion, conditioning regimen, and patient age.
Adjusted for disease, GVHD prophylaxis, in vivo T-cell depletion, conditioning regimen, and patient age.
Adjusted for disease, donor age, conditioning regimen, graft type, in vivo T-cell depletion, GVHD prophylaxis, and Karnofsky score.
Adjusted for disease, disease stage, conditioning regimen, and year of transplantation.
Adjusted for GVHD prophylaxis.